Multiple Sclerosis
Pipeline by Development Stage
Drug Modality Breakdown
Multiple Sclerosis is a $5.1B market in the mature/consolidating stage with established disease-modifying therapies dominating the landscape.
Key Trends
- Data quality issue: non-primary indications incorrectly included in market size calculation, inflating true MS market
- Established immunomodulatory agents (interferons, monoclonal antibodies) driving bulk of primary-indication revenue
- Patent cliffs approaching for key products between 2027-2036, creating genericization pressure
Career Verdict
Moderate career opportunity: solid market size and hiring, but mature positioning limits explosive growth potential; best for commercialization and lifecycle management specialists rather than pipeline-driven roles.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | AUBAGIO (teriflunomide) | Sanofi | $354M | 48% | PEAK | Stable | 8.2yr |
| 2 | OCREVUS (ocrelizumab) | Roche | $157M | 21% | PEAK | Growing | |
| 3 | BETASERON (interferon beta-1b) | Bayer | $103M | 14% | LOE_APPROACHING | Declining | |
| 4 | MAYZENT (siponimod) | Novartis | $80M | 11% | PEAK | Stable | 9.9yr |
Drug Class Breakdown
market-leading monotherapy
growing monoclonal antibody class
legacy therapy declining
established immunosuppressant
symptomatic relief focused
Career Outlook
StableMultiple Sclerosis represents a stable, mature market with entrenched players and predictable revenue streams, making it ideal for professionals seeking tenure and expertise-building over explosive growth. Commercial roles dominate hiring, signaling that companies are competing on market access, patient education, and loyalty programs rather than product innovation. Pipeline activity is solid but incremental; career advancement will depend on mastering reimbursement, health economics, and patient-centricity rather than shepherding breakthrough therapies.
Breaking In
Entry-level candidates should target Commercial, Medical Affairs, or Market Access roles at tier-1 companies (Sanofi, Roche, AbbVie, Novartis) where you will build deep MS expertise and benefit from established training infrastructure.
For Experienced Professionals
Experienced professionals should differentiate on HEOR, payer strategy, and lifecycle management expertise; the patent cliff timeline (2027-2036) creates opportunities to lead market transition planning and identify adjacent indications for pipeline products.
In-Demand Skills
Best For
Hiring Landscape
MS disease area supports 5,157 jobs across 15 companies, with heavy concentration in Commercial (1,060 jobs) and Manufacturing (623 jobs), reflecting mature market dynamics. Top hiring companies (AbbVie, Amgen, Roche, Sanofi) are leveraging scale to drive market access and patient support programs. Salary ranges from $137K (IT) to $252K (Commercial), with significant opportunity for field-based roles.
By Department
Highest-paying roles are in Commercial and R&D; Manufacturing and IT offer lower salaries but stability; MS hiring is driven by market access expansion and reimbursement complexity rather than innovation.
On Market (9)
Approved therapies currently available
Competitive Landscape
92 companies ranked by most advanced pipeline stage
+62 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 6,558 patients across 50 trials
Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
Natalizumab and Chronic Inflammation
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Towards Personalized Dosing of Natalizumab in Multiple Sclerosis
Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
Resistance Training and Amino Pyridine in Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
A Trial of Neuroprotection With ACTH in Acute Optic Neuritis
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri
Rehabilitation Study in MS Patients
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
FOCUS Fatigue Outcome in Copaxone USers
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Related Jobs in Neurology
Regional Business Director, (West Region), Immunology
Regional Business Director, (Southeast Region), Immunology
Regional Business Director, (South Central Region), Immunology
Regional Business Director, (Northeast Region), Immunology
Regional Business Director, (Midwest Region), Immunology
Senior Manager/Associate Director, Program Management
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.